Oxford Immunotec Global PLC (NASDAQ:OXFD) is expected to report third quarter earnings results, before market open, on Tuesday 3rd November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.05 per share.
Looking ahead, the full year loss are expected at $ 0.67 per share on the revenues of $ 57.03 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 18.00 million ~ $ 19.00 million
Full Year 2020 topline are forecasted in a range of$ 78.00 million ~ $ 81.00 million
Click Here For More Historical Outlooks Of Oxford Immunotec Global PLC
Previous Quarter Performance
Oxford Immunotec Global PLC outlined loss for the second quarter of $ 0.37 per share, from the revenue of $ 5.84 million. The consensus estimates are loss of $ 0.30 per share from $ 5.80 million in revenue. The bottom line results missed street analysts by $ 0.07 or 23.33 percent, at the same time, top line results outshined analysts by $ 0.04 million or 0.69 percent.
Stock Performance
Shares of Oxford Immunotec Global PLC traded up $ 0.20 or 1.78 percent on Monday, reaching $ 11.44 with volume of 131.80 thousand shares. Oxford Immunotec Global PLC has traded high as $ 11.97 and has cracked $ 11.06 on the downward trend
The closing price of $ 11.44, representing a 34.29 % increase from the 52 week low of $ 8.37 and a 36.75 % decrease over the 52 week high of $ 17.77.
The company has a market capital of $ 296.93 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Oxford Immunotec Global PLC will be hosting a conference call at 8:00 AM eastern time on 3rd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.oxfordimmunotec.com
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. The company develops and markets T-SPOT.TB test used to test for tuberculosis.
